CRISPR Therapeutics AG $CRSP Shares Sold by KBC Group NV

KBC Group NV trimmed its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 40.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,224 shares of the company’s stock after selling 1,526 shares during the period. KBC Group NV’s holdings in CRISPR Therapeutics were worth $108,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. SVB Wealth LLC purchased a new position in shares of CRISPR Therapeutics during the first quarter worth about $25,000. Costello Asset Management INC purchased a new stake in shares of CRISPR Therapeutics in the 1st quarter valued at about $27,000. Atlantic Union Bankshares Corp acquired a new stake in shares of CRISPR Therapeutics in the 2nd quarter valued at about $33,000. Quantbot Technologies LP grew its stake in CRISPR Therapeutics by 272.4% during the 1st quarter. Quantbot Technologies LP now owns 1,337 shares of the company’s stock worth $45,000 after buying an additional 978 shares during the last quarter. Finally, IFP Advisors Inc grew its stake in CRISPR Therapeutics by 24.6% during the 2nd quarter. IFP Advisors Inc now owns 916 shares of the company’s stock worth $45,000 after buying an additional 181 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. initiated coverage on CRISPR Therapeutics in a report on Thursday, September 18th. They issued an “overweight” rating and a $70.00 price objective for the company. Barclays upped their price target on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Wedbush decreased their price target on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating for the company in a research note on Wednesday, November 5th. Bank of America lifted their price objective on shares of CRISPR Therapeutics from $78.00 to $93.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Finally, Needham & Company LLC decreased their target price on shares of CRISPR Therapeutics from $81.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, November 10th. Eleven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $67.84.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 50,895 shares of the stock in a transaction on Friday, October 17th. The stock was sold at an average price of $67.91, for a total value of $3,456,279.45. Following the completion of the transaction, the chief executive officer owned 254,201 shares in the company, valued at approximately $17,262,789.91. This represents a 16.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel James R. Kasinger sold 1,076 shares of the firm’s stock in a transaction on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total value of $71,661.60. Following the completion of the sale, the general counsel directly owned 83,402 shares of the company’s stock, valued at approximately $5,554,573.20. This trade represents a 1.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 56,213 shares of company stock worth $3,810,458 in the last ninety days. 4.30% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics Stock Up 1.9%

Shares of NASDAQ:CRSP opened at $50.23 on Friday. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $78.48. The company has a 50-day moving average price of $62.68 and a 200 day moving average price of $54.01. The company has a market cap of $4.79 billion, a P/E ratio of -8.99 and a beta of 1.89.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, November 10th. The company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.15. The company had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $8.74 million. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%. Analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.